Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB) today and set a price target of $60.00. The company’s shares closed last Wednesday at $28.17.
According to TipRanks.com, Olson is ranked 0 out of 5 stars with an average return of -6.9% and a 41.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
89bio has an analyst consensus of Moderate Buy, with a price target consensus of $60.00.
See today’s analyst top recommended stocks >>
Based on 89bio’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.54 million. In comparison, last year the company had a GAAP net loss of $4.44 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
